190 related articles for article (PubMed ID: 25039088)
1. [Editorial. Monographic: Active surveillance in prostate cancer].
Rubio-Briones J; Narbón ES
Arch Esp Urol; 2014 Jun; 67(5):369-71. PubMed ID: 25039088
[No Abstract] [Full Text] [Related]
2. Editorial comment.
Carroll PR; Whitson JM
Urology; 2011 Apr; 77(4):984-5. PubMed ID: 21477729
[No Abstract] [Full Text] [Related]
3. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
Bartoletti R; Cai T
Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
[No Abstract] [Full Text] [Related]
4. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
5. [Prostatectomy vs. "watchful waiting" in early prostate cancer].
Markun S
Praxis (Bern 1994); 2014 Jul; 103(15):909-10. PubMed ID: 25051936
[No Abstract] [Full Text] [Related]
6. Re: Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Taneja SS
J Urol; 2015 Jan; 193(1):128-9. PubMed ID: 25523659
[No Abstract] [Full Text] [Related]
7. Expert panel advocates surveillance for men with low-risk prostate cancer.
Slomski A
JAMA; 2012 Jan; 307(2):133. PubMed ID: 22235075
[No Abstract] [Full Text] [Related]
8. Active Surveillance for Localized Prostate Cancer: No Increased Mortality, but Higher Rates of Clinical Progression.
Ebell MH
Am Fam Physician; 2017 Feb; 95(3):196. PubMed ID: 28145675
[No Abstract] [Full Text] [Related]
9. Watchful waiting for prostate cancer: a review article.
Chodak GW; Warren KS
Prostate Cancer Prostatic Dis; 2006; 9(1):25-9. PubMed ID: 16402090
[TBL] [Abstract][Full Text] [Related]
10. Active Surveillance Versus Treatment of Prostate Cancer: Should Metastasis Be the Primary End Point?
D'Amico AV
J Clin Oncol; 2017 May; 35(15):1638-1640. PubMed ID: 28240975
[No Abstract] [Full Text] [Related]
11. Active Surveillance for Prostate Cancer.
Matulewicz RS; Weiner AB; Schaeffer EM
JAMA; 2017 Dec; 318(21):2152. PubMed ID: 29209723
[No Abstract] [Full Text] [Related]
12. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Gallina A
Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
[No Abstract] [Full Text] [Related]
13. Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Yossepowitch O
Eur Urol; 2010 Apr; 57(4):639-40. PubMed ID: 19299071
[No Abstract] [Full Text] [Related]
14. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
Tosoian JJ; Trock BJ; Landis P; Feng Z; Epstein JI; Partin AW; Walsh PC; Carter HB
J Clin Oncol; 2011 Jun; 29(16):2185-90. PubMed ID: 21464416
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance for prostate cancer.
Thompson IM; Klotz L
JAMA; 2010 Dec; 304(21):2411-2. PubMed ID: 21119090
[No Abstract] [Full Text] [Related]
18. [Active surveillance for the secondary prevention of prostate cancer].
Seisen T; Rouprêt M; Azzouzi AR; Cussenot O; Rozet F
Prog Urol; 2012 Feb; 22(2 Suppl 1):H10-4. PubMed ID: 22445521
[No Abstract] [Full Text] [Related]
19. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
Albertsen P
Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
[No Abstract] [Full Text] [Related]
20. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
